<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739150</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0447</org_study_id>
    <nct_id>NCT04739150</nct_id>
  </id_info>
  <brief_title>An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options</brief_title>
  <official_title>Medical Need Program With Ofev® (Nintedanib) for the Treatment of Adult Patients With Non-IPF (Idiopathic Pulmonary Fibrosis) Chronic Fibrosing Interstitial Lung Diseases (ILDs) With a Progressive Phenotype (PF-ILD's)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This Expanded Access Program in Belgium is open to people with different lung diseases. This&#xD;
      program provides a medicine called nintedanib to people who have no alternative treatment&#xD;
      options. They can participate if they have a type of lung disease called non-IPF ILDs&#xD;
      (chronic fibrosing interstitial lung diseases with a progressive phenotype other than&#xD;
      idiopathic pulmonary fibrosis).&#xD;
&#xD;
      Participants take 2 capsules of nintedanib a day. The treating physician checks the health of&#xD;
      the participants and notes health problems that could have been caused by nintedanib.&#xD;
      Participants receive nintedanib as long as they benefit or until nintedanib becomes&#xD;
      commercially available in Belgium.&#xD;
&#xD;
      For a patient to participate in this program, their treating physician should apply to&#xD;
      Boehringer Ingelheim.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Lung Diseases, Interstitial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nintedanib</intervention_name>
    <description>nintedanib</description>
    <other_name>Ofev®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is not eligible for a clinical trial running with Ofev® and/or a clinical&#xD;
             trial running in the envisaged indication of this program.&#xD;
&#xD;
          -  The patient cannot be satisfactorily treated with the approved and commercially&#xD;
             available alternative treatments, in accordance with clinical guidelines, because of&#xD;
             efficacy and/or safety issues.&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients diagnosed with ILD who fulfilled at least 1 of the following criteria for&#xD;
             PF-ILD within 24 months prior to inclusion in this Medical Need Program (MNP):&#xD;
&#xD;
               -  Clinically significant decline in Forced Vital Capacity (FVC) % predicted based&#xD;
                  on a relative decline of ≥10%&#xD;
&#xD;
               -  Marginal decline in FVC % predicted based on a relative decline of ≥5 to &lt;10%&#xD;
                  combined with worsening of respiratory symptoms&#xD;
&#xD;
               -  Marginal decline in FVC % predicted based on a relative decline of ≥5% to &lt;10%&#xD;
                  combined with increasing extent of fibrotic changes on chest high resolution&#xD;
                  computed tomography (HR-CT) imaging&#xD;
&#xD;
               -  Worsening of respiratory symptoms as well as increasing extent of fibrotic&#xD;
                  changes on chest HR-CT imaging.&#xD;
&#xD;
          -  The treating physician must be a qualified pulmonologist with sufficient experience in&#xD;
             treating patients with ILD and sufficient knowledge to administer Ofev®, and states to&#xD;
             comply with the following requirements to claim this experience:&#xD;
&#xD;
               -  Participates/has participated in clinical trials, in the scope of interstitial&#xD;
                  lung diseases or has fulfilled a residency or fellowship program in ILD&#xD;
&#xD;
               -  Is part of a multidisciplinary team, that has treated ≥25 ILD patients within a&#xD;
                  random uninterrupted timeframe of 24 months&#xD;
&#xD;
               -  The multidisciplinary team exists at least of the following specialist physicians&#xD;
                  with experience in management of interstitial lung diseases: a pulmonologist, a&#xD;
                  radiologist, a pathologist, and a rheumatologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in&#xD;
             patients with severe renal impairment (&lt;30 ml/min creatinine clearance). These&#xD;
             patients are therefore excluded from the program.&#xD;
&#xD;
          -  The safety and efficacy of nintedanib have not been investigated in patients with&#xD;
             hepatic impairment classified as Child Pugh B and C. Treatment of patients with&#xD;
             moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with Ofev® is not&#xD;
             recommended.&#xD;
&#xD;
          -  The safety and efficacy of Ofev® in children aged 0-18 years have not been&#xD;
             established. No data are available. Non-adult patients are therefore excluded.&#xD;
&#xD;
          -  Hypersensitivity to nintedanib, to peanut or soya, or to any of the excipients listed&#xD;
             in section 6.1. of the SMPC.&#xD;
&#xD;
          -  Diagnosis of IPF as Ofev® can be obtained through reimbursed product in this&#xD;
             indication.&#xD;
&#xD;
          -  Patients at known risk for bleeding including patients with inherited predisposition&#xD;
             to bleeding or patients receiving a full dose of anticoagulative treatment were not&#xD;
             included in the clinical trials. Non-serious and serious bleeding events, some of&#xD;
             which were fatal, have been reported in the post-marketing period (including patients&#xD;
             with or without anticoagulant therapy or other medicinal products that could cause&#xD;
             bleeding). Therefore, these patients should only be treated with Ofev if the&#xD;
             anticipated benefit outweighs the potential risk.&#xD;
&#xD;
          -  Ofev® should not be used in patients with severe pulmonary hypertension.&#xD;
&#xD;
          -  Patients with a recent history of myocardial infarction or stroke. Further exclusion&#xD;
             criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalst - HOSP Onze-Lieve-Vrouw</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Valerie Adam</last_name>
      <phone>+32 53 724289</phone>
      <email>valerie.adam@olvz-aalst.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Anderlecht</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Benjamin Bondue</last_name>
      <phone>+32 (0)486 65 68 65</phone>
      <email>Benjamin.Bondue@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Hans Slabbynck</last_name>
      <phone>+32 (0)3 280 35 63</phone>
      <email>hans.slabbynck@skynet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Winand Van Rompaey</last_name>
      <phone>+32 3 6505325</phone>
      <email>winand.van.rompaey@klina.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Samuel Debontridder</last_name>
      <phone>+32 2 4776012</phone>
      <email>samuel.debontridder@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Antoine Froidure</last_name>
      <phone>+32 02 7642832</phone>
      <email>antoine.froidure@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIV UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Guy Brusselle</last_name>
      <phone>+32 9 3322672</phone>
      <email>guy.brusselle@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis - Campus Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jokke Wynants</last_name>
      <phone>+32 11 699615</phone>
      <email>Jokke.Wynants@jessazh.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kortrijk - HOSP AZ Groeninge Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tom Moerman</last_name>
      <phone>+32 56 633340</phone>
      <email>tom.moerman@azgroeninge.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Wim Wuyts</last_name>
      <phone>+32 16 34 68 02</phone>
      <email>wim.wuyts@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Julien Guiot</last_name>
      <phone>+32 4 284 49 01</phone>
      <email>J.Guiot@chuliege.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roeselare - HOSP AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Hannelore Bode</last_name>
      <phone>+32 51 237216</phone>
      <email>Hannelore.Bode@azdelta.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sint-Niklaas - HOSP AZ Nikolaas (Campus St-Niklaas)</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Yvoir - UNIV UCL de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Caroline Dahlqvist</last_name>
      <phone>+32 (0) 81 42 33 66</phone>
      <email>caroline.dahlqvist@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

